분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-02-26 09:25:05 , Hit : 2041
 FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation


By Jennifer Booton/
Published February 24, 2014/
FOXBusiness

Bristol-Myers Squibb Test Tubes
Bristol-Myers Squibb



Bristol-Myers Squibb’s (BMY) investigational treatment for hepatitis C infection was awarded “breakthrough therapy designation” on Monday by U.S. drug regulators.

The U.S. Food and Drug Administration has only approved four breakthrough therapies since the FDA’s Safety and Innovation Act was signed into law in July 2012.

The rare designation is intended to expedite the development and review process of drugs for serious or life-threatening conditions. These drugs are put on a fast-track approval program and given intensive guidance from the FDA.

The approval of Bristol-Myers’ combination therapy for the treatment of genotype 1b chronic hepatitis C infection follows preliminary data from an ongoing late-stage trial.

In that study, the New York-based drug giant is evaluating the all-oral regimen of  daclatasvir (DCV), an investigational NS5A replication complex inhibitor, and asunaprevir (ASV), an investigational NS3 protease inhibitor, without existing hepatitis C drug ribavirin.

This is the second DCV-based regimen to get FDA breakthrough designation, which        Bristol-Myers said further underscores its “potential to help address the high unmet needs of the HCV patient population.” The first was submitted by Gilead Science (GILD) in 2013.

Roughly 170 million people worldwide are infected with hepatitis C, including an estimated 2.7  million to 3.9 million chronically infected in the U.S. Many of these people have been infected for decades, putting them at heightened risk for developing serious, potentially life-threatening liver disease.

"This is an important milestone for Bristol-Myers Squibb as we continue our strategic focus on the development of innovative medicines to address areas of high unmet medical need, where potential expedited review can make a critical difference for patients,” said Brian Daniels, senior vice president of research and development in Bristol-Myers’ Global Development and Medical Affairs group.

The European Medicines Agency is reviewing a similar Bristol-Myers therapy under an accelerated regulatory review. The drug giant also filed an application for approval in Japan in October 2013.

Its shares were up 0.70% to $54.51 in recent trade.



Follow Jennifer Booton on Twitter at @Jbooton







847   CRISPR Reverses Disease Symptoms in Living Animals for First Time  이성욱 2014/04/01 1689
846   약물 생산을 보다 저렴하고 환경친화적으로 만드는데 도움을 주는 바이오 역합성  이성욱 2014/03/26 2116
845   J&J-Medivir Drug for Hepatitis C Recommended by EU Regulator  이성욱 2014/03/24 2022
844   스트레스를 받는 뇌세포는 알츠하이머로부터 보호작용을 한다  이성욱 2014/03/24 1932
843   RNA 치료제 등 3대 R&D 트렌드  이성욱 2014/03/18 2020
842   막다른 골목에 몰린 STAP 세포  이성욱 2014/03/18 1933
841   암 세포의 혈관 밖 이동을 돕는 자외선  이성욱 2014/03/13 2168
840   유전자 편집방법을 이용한 HIV 치료  이성욱 2014/03/10 2088
839   Merck hepatitis C drugs work in HIV co-infected patients -study  이성욱 2014/03/08 1733
838   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1663
837   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1822
836   인체 '게놈 분석 1000달러 시대' 왔다  이성욱 2014/02/28 2116
  FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation  이성욱 2014/02/26 2041
834   숙주 세포 핵의 바아러스 DNA 분해  이성욱 2014/02/26 2280
833   Genetically Altered Stem Cells Generate Engineered Cartilage  이성욱 2014/02/22 2110
832   자궁경부암 유발 바이러스에도 효과를 보이는 HIV 약물  이성욱 2014/02/21 2410
831   美 연구팀, ‘원숭이 아바타’ 실험 성공시켰다  이성욱 2014/02/20 2132
830   Small non-coding RNAs could be warning signs of cancer  이성욱 2014/02/18 1817
829   Gilead submits fixed-dose combination ledipasvir/sofosbuvir HCV tablet for FDA approval  이성욱 2014/02/12 2391
828   Researchers turn adult cells back into stem cells  이성욱 2014/01/30 1668

[이전 10개] [1]..[21] 22 [23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN